(S)-N-(5-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1 | CAS:1223403-58-4

中文名称:	(S)-N-(5-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1
英文名称:	(S)-N-(5-((R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CAS.No:	1223403-58-4	CAS 相关:
MDL No:
分子式:	C₂₁H₂₂F₂N₆O₂
分子量:	428.44	密度:
熔点:		沸点:
储藏条件:
危险安全标识:

中文名称:

(S)-N-(5-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1

英文名称:

(S)-N-(5-((R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

CAS.No:

1223403-58-4

CAS 相关:

MDL No:

分子式:

C₂₁H₂₂F₂N₆O₂

分子量:

428.44

密度:

熔点:

沸点:

储藏条件:

危险安全标识:

* 如果需要咨询更多不同包装的价格，请您联系客服为您查询报价。
* 订购成功后，将从离您最近的仓库发货，如果其中一个仓库中库存不足，我们将从另外一个仓库发货以减少交货时间。

中文名称：: (S)-N-(5-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1

中文别名：: 拉罗替尼;LOXO-101

英文名称：: (S)-N-(5-((R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

英文别名：: LOXO-101;LOXO-101 ARRY-470;Larotrectinib;ARRY470;ARRY-470;LOXO 101;(3S)-N-[5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxamide;PF9462I9HX;(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;Vitrakvi;ARRY 470;1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-;1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-;Larotrectinib [USAN:IN;Larotrectin;Larotrectinib [INN];(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;AKOS027338709;Larotrectinib (LOXO-101 free base);LAROTRECTINIB [USAN];C21H22F2N6O2;BDBM136597;CHEMBL3889654;CS-5722;NSC-785570;Larotrectinib (USAN/INN);example 14 (US8865698 B2);(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;s5860;3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;US8865698, 14;(S)-N-(5 -((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;LAROTRECTINIB [WHO-DD];NSC801004;(3S)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin -1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;1223403-58-4;(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;DB14723;NSC785570;UNII-PF9462I9HX;ARRY-470;ARRY 470 : LOXO-101; LOXO101; Larotrectinib;BAY-2757556;GTPL8909;BCP16262;BAY2757556;(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3 yl)-3-hydroxypyrrolidine-1-carboxamide;Larotrectinib [USAN:INN];AS-35231;EX-A1981;L01XE53;BRD-K36574127-001-01-3;NYNZQNWKBKUAII-KBXCAEBGSA-N;NSC-801004;LAROTRECTINIB [MI];MFCD28902192;larotrectinibum;DTXSID101020707;example 14 [US8865698 B2];(3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;LOXO101;NS00133777;AC-33660;D11137;(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-pyrrolidine-1-carboxamide;(3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide;HY-12866;(3S)-N-(5-((2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDIN- 1-YL)PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE- 1-CARBOXAMIDE;ARRY-470; larotrectinib;Q27081513;EN300-7411765;(3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide;SCHEMBL2241012